Products
Valeant » Products & Pipeline
Skip to content Home About Valeant Key Facts and History Board of Directors & Management Corporate Governance By-Laws Governance Guidelines Committee Structure Committee Charters Code of Business Conduct & Ethics Other Ethical Disclosures Sales & Marketing Compliance
Valeant » Products & Pipeline » Branded Generics
Valeant's Branded Generics division develops, manufactures and markets products that are the therapeutic equivalent to their brand name counterparts
Valeant » Products & Pipeline » Dermatology » Cloderm®
Cloderm® (tretinoin) Gel, 0.05% is a topical retinoid indicated for the treatment of mild to moderate acne vulgaris, available through doctor's prescription only.
Valeant » Products & Pipeline » Neurology » Migranal®
Migranal (dihydroergotamine mesylate, USP) Nasal Spray provides relief at any time during a migraine, whether early or late in the attack.
Valeant » Products & Pipeline » Development Pipeline
Valeant and its partners are focusing on developing new medicines across the neurology and dermatology therapeutic areas.
Valeant » Products & Pipeline » Dermatology » Atralin®
Atralin® (tretinoin) Gel, 0.05% is a topical retinoid indicated for the treatment of mild to moderate acne vulgaris, available through doctor's prescription only.
Valeant » Products & Pipeline » Consumer Brands » Dermadrate®
Dermadrate® is a gentle, yet effective skin care regimen scientifically shown to improve the appearance of skin aging, sun damage, blotchiness and roughness.
Valeant » Products & Pipeline » Development Pipeline » Dermatology Pipeline
Valeant and its partners are focusing on developing new medicines across the neurology and dermatology therapeutic areas.
Valeant » Products & Pipeline » Development Pipeline » Neurology Pipeline
Valeant and its partners are focusing on developing new medicines across the neurology and dermatology therapeutic areas.
Valeant » Products & Pipeline » Neurology » Tasmar®
TASMAR® (tolcapone) is an adjunct oral medication that is used in combination levodopa and carbidopa for patients with severe Parkinson's disease who are not responding satisfactorily to, or are not appropriate candidates for, other adjunct therapies.
